The focus and prospect of prostate cancer research.
- Author:
Hanzhong LI
1
,
2
;
Email: LIHANZHONG@MEDMAIL.COM.CN.
;
Dexin DONG
3
Author Information
1. Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
2. Email: lihanzhong@medmail.com.cn.
3. Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
Biopsy;
Brachytherapy;
China;
Early Detection of Cancer;
Humans;
Laparoscopy;
Male;
Prognosis;
Prostate-Specific Antigen;
blood;
Prostatic Neoplasms;
diagnosis;
radiotherapy;
surgery;
Robotic Surgical Procedures;
Testosterone;
blood;
Urinary Incontinence
- From:
Chinese Journal of Surgery
2015;53(4):253-256
- CountryChina
- Language:Chinese
-
Abstract:
The incidence and mortality of prostate cancer in China are increasing year by year. The review is focused on current hot prospects of prostate cancer. The value of serum prostate specific antigen (PSA) screening is still controversial, and PSA screening in high-risk groups is recommended for early diagnosis of prostate cancer. Prostate biopsy including transrectal approach and perineal approach, and two methods have both advantages and disadvantages. There is significant correlation between testosterone levels and the prognosis of prostate cancer, and the monitoring of testosterone level contributes to the treatment. The main complications of radical resection of prostate cancer is urinary incontinence and erectile dysfunction, three-dimensional laparoscopic and robot assisted laparoscopic techniques have obvious advantages in radical operation. Brachytherapy is another option for radical treatment, with relaxed age limit, low incidence of erectile dysfunction, urinary incontinence and reliable curative effect. The diagnosis and treatment of new technologies include such as MRI dynamic enhancement scan, ¹⁸F-fluoroethyl PET/CT, ultrasound contrast technology, prostate cancer immunotherapy, et al.
